The index, which comprises of 48 companies, includes phamaceutical giant Glaxo Smithkline, Oxford Glycosciences, and Galen Holdings, which will release its results on 13 November. The index was launched in conjunction with the BioIndustry Association.
Among its principal aims, the index seeks to boost smaller healtcare companies by putting them alongside larger ones, provide investors and companies with opportunities to meet, and promote the sector internationally with the support of LSE infrastructure.
Companies included on the index must be eligible or included in techMARK, and classified in the pharmaceuticals and medical equipment and supplies sector of the FTSE global qualification system.
Martin Wheatley, deputy chief executive of the London Stock Exchange will speak about the index at Deloitte & Touche’s quarterly techMARK review, which takes place next Tuesday.